“…Since their inception 30 years ago, DNA-encoded library (DEL) screens have become an indispensable tool for finding small-molecule binders from which to start drug development campaigns. − Typically, DELs consist of a pooled collection of millions (or even billions) of compounds, each covalently appended with a unique DNA tag that encodes the structure of the covalently attached compound. , DELs offer several advantages over conventional screening technologies by enabling hit affinity selection using small amounts of proteins and multiplexed DEL inputs, thereby reducing the cost, effort, and time associated with hit finding. ,, The success of DELs is further corroborated by the growing number of publications from academia and industry reporting the identification of potent and selective hits for diverse biological targets. ,,, Although DEL technology enables the screening of vast collections of compounds, due to the combinatorial nature of DEL synthesis, the diversity of intrinsic DEL chemotypes depends on the development of novel DEL-compatible bond-forming reactions, ideally using widely available building blocks as diversity elements. , For a reaction to be widely useful for producing DELs in solution-phase formats, it should be adapted to fit key constraints such as tolerance to aqueous reaction conditions, amenability to miniaturization, wide substrate scope, high reproducibility and maintain the integrity of DNA tags . To support the Janssen DEL pipeline, we have a continuing interest in developing new DEL chemistries that can address DEL synthetic gaps to essential medicinal chemistry chemotypes or that enable use of under-utilized building block classes. , …”